About the Authors

Stina Wichert

stina.wichert@med.lu.se

Affiliation Department of Hematology, Skåne University Hospital and Lund University, Lund, Sweden

Gunnar Juliusson

Affiliation Department of Hematology, Skåne University Hospital and Lund University, Lund, Sweden

Åsa Johansson

Affiliation Clinical Immunology and Transfusion Medicine, University and Regional Laboratories Region Skåne, Lund, Sweden

Elisabeth Sonesson

Affiliation Clinical Development, BioInvent International AB, Lund, Sweden

Ingrid Teige

Affiliation Research, BioInvent International AB, Lund, Sweden

Anna Teige Wickenberg

Affiliation Clinical Development, BioInvent International AB, Lund, Sweden

Björn Frendeus

Affiliation Research, BioInvent International AB, Lund, Sweden

Magnus Korsgren

Affiliation Clinical Development, BioInvent International AB, Lund, Sweden

Markus Hansson

Affiliation Department of Hematology, Skåne University Hospital and Lund University, Lund, Sweden

Competing Interests

We have the following interests: ES, IT, ATW, BF, MK are, or were, full-time employees of BioInvent International AB at the time of this study. IT, ATW and BF are currently employed and own stock (>50,000) in the company. BF and MH are inventors on patents relating to BI-505 and anti-ICAM antibody therapy. These declarations do not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceptualization: BF MK MH. Data curation: SW ATW MH. Formal analysis: SW MH. Funding acquisition: BF MK. Investigation: SW GJ ÅJ ES. Methodology: SW ÅJ ES IT BF MK MH. Project administration: ES MK SW MH. Supervision: BF MK MH. Visualization: SW. Writing – original draft: SW. Writing – review & editing: SW GJ ÅJ ES IT ATW BF MK MH.